Prognostic factors of adjuvant chemotherapy discontinuation among stage III colon cancer patients: A survey of medical oncologists and a systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Prognostic factors of adjuvant chemotherapy discontinuation among stage III colon cancer patients: A survey of medical oncologists and a systematic review and meta‐analysis

Published:2020-01-21 Issue:5 Volume:9 Page:1613-1627
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Boyne Devon J.¹²^ORCID,O'Sullivan Dylan E.³,Heer Emily V.²,Hilsden Robert J.¹⁴,Sajobi Tolulope T.¹,Cheung Winson Y.⁴⁵,Brenner Darren R.¹²⁵,Friedenreich Christine M.¹²⁵^ORCID

Affiliation:

1. Department of Community Health Sciences Cumming School of Medicine University of Calgary Calgary Alberta Canada

2. Department of Cancer Epidemiology and Prevention Research CancerControl Alberta Alberta Health Services Calgary Alberta Canada

3. Department of Public Health Sciences Faculty of Medicine Queen's University Kingston Ontario Canada

4. Department of Medicine Cumming School of Medicine University of Calgary Calgary Alberta Canada

5. Department of Oncology Cumming School of Medicine University of Calgary Calgary Alberta Canada

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2843

Reference42 articles.

1. Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

2. Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report

3. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

4. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

5. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physical decline, falls, and hospitalization among vulnerable older patients in the trajectory of colorectal cancer treatment;Journal of Geriatric Oncology;2024-09

2. LGR5 as a Therapeutic Target of Antibody-Functionalized Biomimetic Magnetoliposomes for Colon Cancer Therapy;International Journal of Nanomedicine;2024-02

3. Optimal adjuvant chemotherapy completion time for stage III colon cancer: a cohort study;Journal of Gastrointestinal Oncology;2021-08

4. Adjuvant chemotherapy for patients with stage II high-risk and III colon cancer: Hindering factors to adherence and impact on long-term survival;Korean Journal of Clinical Oncology;2021-06-30

5. Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer;JAMA Network Open;2021-03-30